Combination of BGJ398 with either a pan-PI3K inhibitor or a specific PIK3CA inhibitor shows synergy in FGFR2 mutant endometrial cancer cell lines

被引：1
|
作者：
Packer, L. [1 ]
Geng, X. [1 ]
Bonazzi, V. [1 ]
Mahon, C. [1 ]
Ju, R. [1 ]
Stephenson, S. [1 ]
Pollock, P. [1 ]
机构：
[1] Queensland Univ Technol, Sch Biomed Sci, Inst Hlth & Innovat, Translat Res Inst, Brisbane, Qld, Australia
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 61卷
关键词：
D O I：
10.1016/S0959-8049(16)61523-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
661
引用
收藏
页码：S148 / S148
页数：1
相关论文
共 50 条
  • [1] Combination synergy of JAK inhibitor, BVB808, and FGFR inhibitor, BGJ398, in an FGFR3-driven multiple myeloma model
    Pinzon-Ortiz, Maria
    Tan, Lujian
    Yao, Yao
    Schlegel, Robert
    Radimerski, Thomas
    Cao, Z. Alexander
    CANCER RESEARCH, 2012, 72
  • [2] Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
    Wang, Dong
    Wang, Min
    Jiang, Nan
    Zhang, Yuan
    Bian, Xing
    Wang, Xiaoqing
    Roberts, Thomas M.
    Zhao, Jean J.
    Liu, Pixu
    Cheng, Hailing
    ONCOTARGET, 2016, 7 (11) : 13153 - 13166
  • [3] Differential response to a dual PI3K/mTOR inhibitor in PIK3CA mutant urothelial cancer patient derived xenografts
    Elbanna, May F.
    Ciamporcero, Eric
    Adelaiye, Remi
    Orillion, Ashley
    Chintala, Sreenivasulu
    Pili, Roberto
    CANCER RESEARCH, 2016, 76
  • [4] PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer
    Nixon, Mellissa J.
    Formisano, Luigi
    Mayer, Ingrid A.
    Estrada, M. Valeria
    Gonzalez-Ericsson, Paula, I
    Isakoff, Steven J.
    Forero-Torres, Andres
    Won, Helen
    Sanders, Melinda E.
    Solit, David B.
    Berger, Michael F.
    Cantley, Lewis C.
    Winer, Eric P.
    Arteaga, Carlos L.
    Balko, Justin M.
    NPJ BREAST CANCER, 2019, 5 (1)
  • [5] PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer
    Mellissa J. Nixon
    Luigi Formisano
    Ingrid A. Mayer
    M. Valeria Estrada
    Paula I. González-Ericsson
    Steven J. Isakoff
    Andrés Forero-Torres
    Helen Won
    Melinda E. Sanders
    David B. Solit
    Michael F. Berger
    Lewis C. Cantley
    Eric P. Winer
    Carlos L. Arteaga
    Justin M. Balko
    npj Breast Cancer, 5
  • [6] Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab
    Cao, Z. Alexander
    Pinzon-Ortiz, Maria
    Chen, Yan
    Li, Xiaoyan
    Beltran, Pedro J.
    Gansert, Jennifer
    Peters, Malte
    Schlegel, Robert
    Schumacher, Karl M.
    Huang, Alan
    CANCER RESEARCH, 2014, 74 (19)
  • [7] Potential antitumor effect of a pan-PI3K inhibitor ZSTK474 on human sarcoma cell lines
    Dan, Shingo
    Tamaki, Naomi
    Namatame, Nachi
    Yoshizawa, Yuya
    Okamura, Mutsumi
    Nishimura, Yumiko
    Yamazaki, Kanami
    Yaguchi, Shin-ichi
    CANCER RESEARCH, 2019, 79 (13)
  • [8] The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
    Cataldo, Maria Letizia
    De Placido, Pietro
    Esposito, Daniela
    Formisano, Luigi
    Arpino, Grazia
    Giuliano, Mario
    Bianco, Roberto
    De Angelis, Carmine
    Veneziani, Bianca Maria
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [9] Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab.
    Cao, Z. Alexander
    Pinzon-Ortiz, Maria
    Chen, Yan
    Li, Xiaoyan
    Beltran, Pedro J.
    Gansert, Jennifer L.
    Peters, Malte
    Schlegel, Robert
    Schumacher, Karl Maria
    Huang, Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] The P13K inhibitor GDC-0032 is selectively potent against PIK3CA mutant breast cancer cell lines and tumors
    Wallin, J. J.
    Edgar, K. A.
    Guan, J.
    Sampath, D.
    Nannini, M.
    Belvin, M.
    Friedman, L. S.
    CANCER RESEARCH, 2013, 73
12345